{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:11:44Z","timestamp":1771884704695,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T00:00:00Z","timestamp":1324339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00044-011-9926-4","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T12:05:12Z","timestamp":1324296312000},"page":"3958-3964","source":"Crossref","is-referenced-by-count":2,"title":["Modeling VEGFR kinase inhibition of aminopyrazolopyridine urea derivatives using topological and physicochemical descriptors: a quantitative structure activity analysis study"],"prefix":"10.1007","volume":"21","author":[{"given":"Ashutosh Kumar","family":"Pandey","sequence":"first","affiliation":[]},{"given":"Omprakash","family":"Tanwar","sequence":"additional","affiliation":[]},{"given":"Girdhar Singh","family":"Deora","sequence":"additional","affiliation":[]},{"given":"Chandrabose","family":"Karthikeyan","sequence":"additional","affiliation":[]},{"given":"N. S.","family":"Hari Narayana Moorthy","sequence":"additional","affiliation":[]},{"given":"Piyush","family":"Trivedi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,12,20]]},"reference":[{"key":"9926_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:JCAM.0000004622.13865.4f","volume":"17","author":"H Assefa","year":"2003","unstructured":"Assefa H, Kamath S, Buolamwini JK (2003) 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aided Mol Des 17:475\u2013493","journal-title":"J Comput Aided Mol Des"},{"key":"9926_CR2","first-page":"7301","volume":"63","author":"JS Beebe","year":"2003","unstructured":"Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG (2003) Pharmacological characterization of CP-547, 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63:7301\u20137309","journal-title":"Cancer Res"},{"issue":"5","key":"9926_CR3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2174\/157340609789117822","volume":"5","author":"D Bhargava","year":"2009","unstructured":"Bhargava D, Karthikeyan C, Moorthy NSHN, Trivedi P (2009) Quantitative structure activity relationship studies of piperazinyl phenylalanine as VLA-4\/VCAM-1 Inhibitors. Med Chem 5(5):446\u2013454","journal-title":"Med Chem"},{"key":"9926_CR4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jmgm.2006.12.001","volume":"26","author":"H Cao","year":"2007","unstructured":"Cao H, Zhang H, Zheng X, Gao D (2007) 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. J Mol Graph Model 26:236\u2013245","journal-title":"J Mol Graph Model"},{"issue":"1","key":"9926_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bmcl.2007.10.018","volume":"18","author":"Y Dai","year":"2008","unstructured":"Dai Y, Hartandi K, Soni NB, Pease LJ, Reuter DR, Olson AM, Osterling DJ, Doktor SZ, Albert DH, Bouska JJ, Glaser KB, Marcotte PA, Stewart KD, Davidsen SK, Michaelides MR (2008) Identification of aminopyrazolopyridine ureas as potent VEGFR\/PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 18(1):386\u2013390","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"9926_CR6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.bulm.2003.12.003","volume":"66","author":"HG D\u00edaz","year":"2004","unstructured":"D\u00edaz HG, Bastida I, Casta\u00f1edo N, Nasco O, Olazabal E, Morales A, Serrano HS, de Armas R (2004) Simple stochastic fingerprints towards mathematical modelling in biology and medicine. 1. The treatment of coccidiosis. Bull Math Biol 66(5):1285\u20131311","journal-title":"Bull Math Biol"},{"key":"9926_CR7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jmgm.2008.10.006","volume":"27","author":"J Du","year":"2009","unstructured":"Du J, Lei B, Qin J, Liu H, Yao X (2009) Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J Mol Graph Model 27:642\u2013654","journal-title":"J Mol Graph Model"},{"key":"9926_CR8","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1021\/jm0301641","volume":"46","author":"DE Gingrich","year":"2003","unstructured":"Gingrich DE, Reddy DR, Iqbal MA, Singh J, Aimone LD, Angeles TS, Albom M, Yang S, Ator MA, Meyer SL, Robinson C, Ruggeri BA, Dionne CA, Vaught JL, Mallamo JP, Hudkins RL (2003) A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J Med Chem 46:5375\u20135388","journal-title":"J Med Chem"},{"key":"9926_CR9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bmc.2005.08.009","volume":"14","author":"MP Gonza\u2032lez","year":"2006","unstructured":"Gonza\u2032lez MP, Caballero J, Tundidor-Camba A, Helguera AM, Fernandez M (2006) Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches. Bioorg Med Chem 14:200\u2013213","journal-title":"Bioorg Med Chem"},{"key":"9926_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00894-003-0148-7","volume":"9","author":"H Gonzalez-Diaz","year":"2003","unstructured":"Gonzalez-Diaz H, Gia O, Uriarte E, Hernadez I, Ramos R, Chaviano M, Seijo S, Castillo JA, Morales L, Santana L, Akpaloo D, Molina E, Cruz M, Torres LA, Cabrera MA (2003) Markovian chemicals \u201cin silico\u201d design (MARCH-INSIDE), a promising approach for computer-aided molecular design I: discovery of anticancer compounds. J Mol Model 9:395\u2013407","journal-title":"J Mol Model"},{"key":"9926_CR11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"D Hicklin","year":"2005","unstructured":"Hicklin D, Ellis L (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011\u20131027","journal-title":"J Clin Oncol"},{"issue":"1","key":"9926_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/14756360701810355","volume":"24","author":"C Karthikeyan","year":"2009","unstructured":"Karthikeyan C, Moorthy NSHN, Trivedi P (2009) QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors. J Enzym Inhibit Med Chem 24(1):6\u201313","journal-title":"J Enzym Inhibit Med Chem"},{"key":"9926_CR13","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1021\/jm020899q","volume":"45","author":"PW Manley","year":"2002","unstructured":"Manley PW, Furet P, Bold G, Bruggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A, Kruger M, Menrad A, Ottow E, Seidelmann D, Siemeister G, Thierauch KH (2002) Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem 45:5687\u20135693","journal-title":"J Med Chem"},{"key":"9926_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbapap.2003.11.010","volume":"1697","author":"PW Manley","year":"2004","unstructured":"Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697:17\u201327","journal-title":"Biochim Biophys Acta"},{"key":"9926_CR15","unstructured":"Molecular design suite TM 3.5 (2006) V-life Sciences Technologies Pvt. Ltd., Pune, India"},{"key":"9926_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.vph.2006.01.005","volume":"44","author":"NM Pandya","year":"2006","unstructured":"Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis-a new target for future therapy. Vasc Pharmacol 44:265\u2013274","journal-title":"Vasc Pharmacol"},{"key":"9926_CR17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.hoc.2004.06.004","volume":"18","author":"A Parikh","year":"2004","unstructured":"Parikh A, Ellis L (2004) The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin N Am 18:951\u2013971","journal-title":"Hematol Oncol Clin N Am"},{"issue":"5","key":"9926_CR18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/157340609789117813","volume":"5","author":"A Patel","year":"2009","unstructured":"Patel A, Karthikeyan C, Moorthy NSHN, Trivedi P (2009) QSAR study on N-(aryl)-4-(azolylethyl) thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. Med Chem 5(5):455\u2013461","journal-title":"Med Chem"},{"issue":"1","key":"9926_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/157340610791208736","volume":"6","author":"A Patel","year":"2010","unstructured":"Patel A, Karthikeyan C, Moorthy NSHN, Trivedi P (2010) QSAR study on hetaryl imidazoles: a novel dual inhibitor of VEGF receptors I and II. Med Chem 6(1):24\u201329","journal-title":"Med Chem"},{"issue":"4","key":"9926_CR20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/ci034039+","volume":"43","author":"M P\u00e9rez Gonz\u00e1lez","year":"2003","unstructured":"P\u00e9rez Gonz\u00e1lez M, Gonzalez D\u00edaz H, Molina Ruiz R, Cabrera MA, Ramos de Armas R (2003) TOPS-MODE based QSARs derived from heterogeneous series of compounds. Applications to the design of new herbicides. J Chem Inf Comput Sci 43(4):1192\u20131199","journal-title":"J Chem Inf Comput Sci"},{"key":"9926_CR21","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1016\/j.bmc.2004.05.035","volume":"12","author":"M P\u00e9rez Gonz\u00e1lez","year":"2004","unstructured":"P\u00e9rez Gonz\u00e1lez M, Dias LC, Helguera AM, Rodr\u00edguez YM, de Oliveira LG, Gomez LT, Diaz HG (2004) TOPS-MODE based QSARs derived from heterogeneous series of compounds. Applications to the design of new anti-inflammatory compounds. Bioorg Med Chem 12:4467\u20134475","journal-title":"Bioorg Med Chem"},{"key":"9926_CR22","doi-asserted-by":"crossref","unstructured":"Reardon D, Friedman HS, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson EF, Serajuddin H, Laurent D, Reitsma D (2003) A phase I trial of PTK787\/ZK222584 (PTK\/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temololomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 22103 (abstract 412)","DOI":"10.1200\/jco.2004.22.90140.1513"},{"key":"9926_CR23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/14756360701450301","volume":"23","author":"BK Sharma","year":"2008","unstructured":"Sharma BK, Sharma SK, Singh P, Sharma S (2008) A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFR alpha tyrosine kinase inhibitors: derivatives of N-phenyl-N\u2032-{4-(4-quinolyloxy)phenyl}urea as antitumor agents. J Enzym Inhibit Med Chem 23:168\u2013173","journal-title":"J Enzym Inhibit Med Chem"},{"key":"9926_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0093-7754(03)70023-2","volume":"30","author":"AL Thomas","year":"2003","unstructured":"Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787\/ZK 222584. Semin Oncol 30:32\u201338","journal-title":"Semin Oncol"},{"key":"9926_CR25","unstructured":"VLife QSARPlus Descriptors classification (2006) V-life Sciences Technologies Pvt. Ltd. Pune, India"},{"key":"9926_CR26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cytogfr.2004.04.003","volume":"15","author":"K Xie","year":"2004","unstructured":"Xie K, Wei D, Shi Q, Huang S (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15:297\u2013324","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-011-9926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00044-011-9926-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-011-9926-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T02:17:56Z","timestamp":1561083476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00044-011-9926-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,20]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["9926"],"URL":"https:\/\/doi.org\/10.1007\/s00044-011-9926-4","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,20]]}}}